Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

Nature Reviews. Drug Discovery
Eugene W M NgAnthony P Adamis

Abstract

Aptamers are oligonucleotide ligands that are selected for high-affinity binding to molecular targets. Pegaptanib sodium (Macugen; Eyetech Pharmaceuticals/Pfizer) is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165, the VEGF isoform primarily responsible for pathological ocular neovascularization and vascular permeability. After nearly a decade of preclinical development to optimize and characterize its biological effects, pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration. Pegaptanib therefore has the notable distinction of being the first aptamer therapeutic approved for use in humans, paving the way for future aptamer applications.

References

Aug 30, 1990·Nature·A D Ellington, J W Szostak
Nov 7, 1995·Proceedings of the National Academy of Sciences of the United States of America·L P AielloL E Smith
Mar 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·J A DoudnaB A Sullenger
Nov 12, 1996·Biochemistry·L S GreenN Janjic
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·M BlindM Famulok
Oct 12, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·C E TuckerD W Drolet
Nov 5, 1999·In Vitro Cellular & Developmental Biology. Animal·C BellM E Wiles
Feb 5, 2000·Science·T Hermann, D J Patel
Aug 17, 2000·The Journal of Biological Chemistry·J ZhangT M Rana
Sep 13, 2000·Journal of Molecular Neuroscience : MN·K L JinD A Greenberg
Oct 18, 2000·The Journal of Clinical Investigation·R R WhiteC P Rusconi
Apr 24, 2001·Journal of the American Society of Nephrology : JASN·Tammo OstendorfJürgen Floege
Oct 9, 2001·Chemistry & Biology·M FamulokG Mayer
Feb 28, 2002·American Journal of Ophthalmology·Michael J TolentinoGerard A Lutty
Jun 19, 2002·Proceedings of the National Academy of Sciences of the United States of America·Britta WlotzkaSven Klussmann
Nov 29, 2002·American Journal of Physiology. Cell Physiology·Shi J LiuJane McHowat
Dec 31, 2002·Investigative Ophthalmology & Visual Science·Karen G CarrasquilloAnthony P Adamis
Jan 21, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·Vivek BalasubramaniamSteven H Abman
Apr 26, 2003·Investigative Ophthalmology & Visual Science·Susumu IshidaAnthony P Adamis

❮ Previous
Next ❯

Citations

Apr 9, 2013·Archivum Immunologiae Et Therapiae Experimentalis·Partha RayRebecca Smock Woodruff
Oct 31, 2006·Analytical and Bioanalytical Chemistry·Subash Chandra Bose Gopinath
Jun 22, 2007·Analytical and Bioanalytical Chemistry·Teresa MairalCiara K O'Sullivan
Jul 25, 2012·Analytical and Bioanalytical Chemistry·Kris P F JanssenJeroen Lammertyn
Mar 10, 2007·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Martin S SpitzerPeter Szurman
Sep 4, 2008·Cell and Tissue Research·Yongping Crawford, Napoleone Ferrara
Oct 17, 2006·Wiener medizinische Wochenschrift·Volker Wacheck
Dec 31, 2010·Japanese Journal of Ophthalmology·Joan W Miller
Mar 21, 2007·Angiogenesis·John BradleyGregory S Robinson
Mar 7, 2007·Journal of Clinical Immunology·Jozélio Freire CarvalhoYehuda Shoenfeld
Feb 16, 2010·Pharmaceutical Research·Esther Eljarrat-BinstockAbraham J Domb
Sep 29, 2012·Cancer Letters·Chang-Keun LimIck Chan Kwon
Aug 24, 2013·Journal of Photochemistry and Photobiology. B, Biology·Dilson SilvaSotiris Missailidis
Jul 7, 2011·Analytical Chemistry·Stephanie de Jong, Sergey N Krylov
Jan 16, 2008·Accounts of Chemical Research·Steven M ShamahSharon T Cload
Jun 20, 2012·Bioconjugate Chemistry·Chiara Da PieveAlan C Perkins
Oct 1, 2013·Bioconjugate Chemistry·Hanieh KhaliliSteve Brocchini
Jan 2, 2013·Chemical Reviews·Venkat Ratnam DevadasuM N V Ravi Kumar
Oct 5, 2010·Journal of the American Chemical Society·Punit P SethEric E Swayze
Jun 6, 2013·Journal of the American Chemical Society·Yuri ImaizumiNaoki Sugimoto
Oct 14, 2008·Journal of the American Chemical Society·Gil Tae Hwang, Floyd E Romesberg
Aug 28, 2010·The Journal of Physical Chemistry. a·Marie-Eve Aubin-TamMatthew J Lang
Oct 26, 2011·ACS Nano·Zhan WuWeihong Tan
Apr 9, 2013·Nature Biotechnology·Michiko KimotoIchiro Hirao
Nov 9, 2007·Nature Biotechnology·Daniel Ricklin, John D Lambris
Aug 30, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Errol B De SouzaDinah W Y Sah
Oct 10, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Leslie N JohnsonRajendra Kumar-Singh
Jun 22, 2010·The Analyst·Xiaojuan Zhang, Vamsi K Yadavalli
Apr 14, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jinpeng WangH Tom Soh
Nov 23, 2011·Nucleic Acid Therapeutics·Stephanie BrandalYolanda M Fortenberry
Aug 6, 2009·Oligonucleotides·Kristina W Thiel, Paloma H Giangrande
Aug 1, 2009·Oligonucleotides·Jung-Sun Cho, Seong-Wook Lee
Jul 20, 2007·Nucleic Acids Research·Chang Geng Peng, Masad J Damha
Sep 11, 2009·Nucleic Acids Research·Jenny L BartonPeter G Stockley
Jul 6, 2011·Nucleic Acids Research·Mark A DitzlerDonald H Burke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.